newsfilter
← Latest News
Business Wire·

Travere Therapeutics Reports First Quarter 2026 Financial Results

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million FDA approval in FSGS expands total addressable FILSPARI patient